Today we launch the first version of the Longevity Intervention Database (LID). There has been a big need in the longevity field to store longevity intervention data on multiple species in one place. In the first version of the LID we have added all the data from the ITP (Intervention Testing Program) to it. The ITP is usually seen as the golden standard for testing interventions in mice and now we have one place where we can find this data structured and visible in a good way. Step by step we will continue to add more data and functionality to the page. I hope you like it and let me know if you have suggestions on improvements or want to help out in filling the database with data
PS. The list on the LID is sorted by maximum lifespan and the interesting thing is that the top ten of all the experiments involve Rapamycin in one or the other way.
I really appreciate this up-to-date summary and its sortability. The obvious study missing (perhaps hasn’t been done?) is rapamycin and 17-a-estradiol, especially for males.
The nice thing is that study is ongoing according to an interview Peter Attia did with Richard Miller last year. This one.
I asked Richard Miller some weeks ago about what dose regime has been chosen and this was his answer:
We did a pilot using Rapa plus 17aE2, and found that the mice lost too much weight.
We then repeated the pilot at lower doses. The weight data are now available, and I think we will be picking the doses of these two agents at our Feb 13 meeting.
Don’t know yet what age we will start - it will depend on the age at the oldest cages of the C2023 mice in mid-Feb. They will be 10 or 11 months old.
So step by step forward. I have already also started to write a proposal to test Rapamycin + Acarbose + 17-a-estradiol. I think we can skip the middle step in the future and invest directly the money on improving the Rapamycin + Acarbose cocktail. Because I don’t think it will give so much big value to test Rapamycin + 17-a-estradiol or some other Rapamycin + X. If we are lucky it can give a bit better results than Rapamycin + Acarbose but we will in the end want to know how the trio performs. So my proposal is that for each year the ITP should at least invest in one intervention to test if the current best cocktail can be improved This will also start to speed things up. Otherwise the lead time will be too long and too costly. We need to be smart here if we want to be the ones who live extra long
The nice thing is that study is ongoing according to an interview Peter Attia did with Richard Miller last year. This one.
